Skip to content
To the full analysis

Sanara MedTech Stock: Balance Sheet and Debt

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

Sanara MedTech has a debt to equity ratio of 8.13 and an interest coverage of 0.9x. Since the end of 2023 debt has exceeded cash, at the end of 2022 it was the other way round.

Daily figure as of 20 Nov 2026

Debt / Equity
8.13
Interest coverage
0.9x
Current ratio
1.8
Cash & equivalents
$16.58M
Total assets
$72.94M
Equity ratio
8.1%
Goodwill
$3.6M
Plus intangible assets of $18.64M
Net debt
$31.61M

Balance Sheet Over Time

At the end of 2022 cash still exceeded debt by $8.14M. In 2022 Sanara MedTech spent $2.52M on acquisitions, and goodwill and intangible assets rose from $4.73M to $35.11M. Goodwill and intangible assets equal 375% of equity. On paper, Sanara MedTech would need 15 years of free cash flow like 2025 to pay off net debt of $31.61M.

Total Assets and Equity Ratio

How large the balance sheet of Sanara MedTech Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$496.29Knot reported separatelynot reported separately−256.1%$1.04M
2007$405.73Knot reported separatelynot reported separately−447.0%$1.51M
2008$151.71Knot reported separatelynot reported separately−211.8%$1.51M
2009$4.77M$4.58Mnot split out48.5%$1.37M
2010$6.78M$4.11Mnot split out42.3%$2.53M
2011$3.83M$432.68Knot split out−100.7%$1.36M
2012$1.39M$344.46Knot split out−273.1%$2.37M
2013$977.15K$293.43Knot split out−252.6%$1.54M
2014$1.5M$242.4Knot split out−55.1%$1.08M
2015$1.39M$191.37Knot split out−91.3%$1.64M
2016$2.17M$140.34Knot split out−19.5%$784.62K
2017$2.22M$117.29Knot split out4.6%$736.81K
2018$3.04M$52.27Knot split out36.6%$768.15K
2019$11.12M$1.47Mnot split out57.5%−$4.51M
2020$9.83M$3.1Mnot split out59.4%$26.02K
2021$36.4M$4.73Mnot split out82.8%−$18.23M
2022$61.04M$35.11M$3.6M68.4%−$8.14M
2023$73.87M$48.53M$3.6M60.4%$6.64M
2024$88.09M$44.61M$3.6M44.2%$16.41M
2025$72.94M$22.24M$3.6M8.1%$31.61M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and Debt

What the Company Owns and Owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$236.3K−$1.27M$1.28M−1.01
2007$781−$1.81M$1.51M−0.83
2008$1.14K−$321.26K$1.51M−4.69
2009−$4.36K$2.31M$1.37M0.59
2010$50.84K$2.87M$2.58M0.9
2011$3.61K−$3.86M$1.37M−0.35
2012$45.86K−$3.81M$2.42M−0.64
2013$44.55K−$2.47M$1.58M−0.64
2014$523.44K−$825.4K$1.61M−1.95
2015$182.34K−$1.27M$1.82M−1.43
2016$833.48K−$423.07K$1.62M−3.82
2017$463.19K$102.54K$1.2M11.7
2018$731.85K$1.11M$1.5M1.35
2019$6.61M$6.61M$2.1M0.33
2020$455.37K$6.15M$481.38K0.08
2021$18.65M$30.64M$425.44K0.01
2022$8.96M$41.83M$819.22K0.02
2023$5.15M$44.83M$11.79M0.26
2024$15.88M$39.4M$32.29M0.83
2025$16.58M$5.93M$48.19M8.13

Debt to equity divides debt by total equity, including non-controlling interests, as S&P calculates it. The equity column shows the part that belongs to shareholders.

Debt of Industry Peers

Sanara MedTech's debt to equity is higher than that of 40 of 40 other stocks in the Medical (Instruments & Supplies) industry.

StockDebt to equityEquity ratio
Kestra Medical Technologies0.1872.4%
STAAR Surgical0.1176.2%
Gerresheimer1.4524.6%
Safilo Group0.2453.1%
Dynavox Group1.8324.3%
AngioDynamics0.0763.9%
Embectano datano data
COLTENE Holding0.4754.4%
Sanara MedTech8.138.1%

Figures from the latest fiscal year. The eight peers closest in market value, largest first.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.